Central Nervous System News and Research

RSS

Potential benefits of Labopharm's novel trazodone formulation published

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.

11 Nov 2009

Epilepsy Therapy Project invests $100,000 in NeuroTherapeutics Pharma

NeuroTherapeutics Pharma, Inc., or NTP, a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced that it received a $100,000 investment from the Epilepsy Therapy Project.

11 Nov 2009

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).

11 Nov 2009

Study suggests a new improved treatment option for children with Hurler's syndrome

Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme - preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.

10 Nov 2009

Individuals with weaker muscles face higher risk for Alzheimer's disease

Individuals with weaker muscles appear to have a higher risk for Alzheimer's disease and declines in cognitive function over time, according to a report in the November issue of Archives of Neurology, one of the JAMA/Archives journals.

10 Nov 2009

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries - a finding that could expand the clinical trial to include people with cervical damage.

10 Nov 2009

AMRI reports $47.7 million total revenue for the third quarter of 2009

AMRI today reported financial and operating results for the third quarter ended September 30, 2009.

9 Nov 2009

National Institutes of Health grants $6-million for brain disease research

Brown University, in collaboration with two other institutions, has been awarded a five-year, $6-million National Institutes of Health program project grant to help determine how a virus that can cause a rare brain disease attaches to host cells.

6 Nov 2009

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

In diseases such as multiple sclerosis, cells of the immune system infiltrate the brain tissue, where they cause immense damage. For many years, it was an enigma as to how these cells can escape from the bloodstream. This is no trivial feat, given that specialized blood vessels act as a barrier between the nervous system and the bloodstream.

6 Nov 2009

Third-quarter financial results for the year 2009 announced by Biovail

Biovail Corporation today announced financial results for the three-month and nine-month periods ended September 30, 2009. To the extent that this news release contains forward-looking statements, investors are cautioned that these statements are based on the Company’s current views, and actual outcomes are not certain.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Takeda Pharmaceuticals strengthens its North American market

Takeda Pharmaceuticals North America, Inc., today announced the incorporation of Takeda Pharmaceuticals Mexico, S.A. de C.V. This expansion strengthens the company's North American presence, bolstering existing operations in the United States and Canada. Takeda Pharmaceuticals Mexico will be headquartered in Mexico City.

4 Nov 2009

Referenced-EEG outperforms STAR*D treatment in depression care

CNS Response, Inc. reported the results of a landmark study presented by Charles DeBattista, D.M.H, M.D., at the U.S. Psychiatric and Mental Health Congress.

4 Nov 2009

New improved enzyme could help facilitate spinal cord injuries

Researchers have developed an improved version of an enzyme that degrades the dense scar tissue that forms when the central nervous system is damaged. By digesting the tissue that blocks re-growth of damaged nerves, the improved enzyme - and new system for delivering it - could facilitate recovery from serious central nervous system injuries.

4 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009.

3 Nov 2009

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

AMRI announced today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company will proceed into preclinical development. AMRI will receive a $750,000 payment from Bristol-Myers Squibb for the completion of this milestone, marking the fifth milestone payment in the ongoing research collaboration between the two companies.

3 Nov 2009

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”).

2 Nov 2009

Vanda Pharmaceuticals announces financial results for the third quarter of 2009

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2009.

2 Nov 2009

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.

2 Nov 2009

Central Nervous System News and Research

Potential benefits of Labopharm's novel trazodone formulation published

Epilepsy Therapy Project invests $100,000 in NeuroTherapeutics Pharma

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

Study suggests a new improved treatment option for children with Hurler's syndrome

Individuals with weaker muscles face higher risk for Alzheimer's disease

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

AMRI reports $47.7 million total revenue for the third quarter of 2009

National Institutes of Health grants $6-million for brain disease research

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

Third-quarter financial results for the year 2009 announced by Biovail

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Takeda Pharmaceuticals strengthens its North American market

Referenced-EEG outperforms STAR*D treatment in depression care

New improved enzyme could help facilitate spinal cord injuries

NIH awards $4 million research grant to AllTranz

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Vanda Pharmaceuticals announces financial results for the third quarter of 2009

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News